Synthego wants to democratize access to the new genetic technologies

Access to therapies is the problem

Paul Dabrowski, the chief executive officer of Synthego, which provides genetically engineered cells to scientists and researchers, worries about a future where access to the genetic technologies that will reshape the world are only available to the few who can afford them.

To hear him tell it, that’s why Dabrowski began working on Synthego in the first place — to democratize access to the new technologies that will give scientists, researchers, and consumers new ways to rewrite the code that has defined human existence.

“People talk about access to the tools, but the question is access to the therapies,” Dabrowski said. “We’re talking about the basis of what does it mean to be human not right now, but in the next 100 years.”

Now, the company has a fresh $110 million in cash from new investors at Founders Fund and the company’s previous backers — 8VC and Menlo Ventures — to try and drive costs down.

Comments are closed.